Drug
Linvoseltamab
Linvoseltamab: highest development phase Post-Market, developed by Regeneron. 6 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Regeneron
Trials
| Drug | Phase | Indication |
|---|---|---|
| Linvoseltamab NCT07609940 | Post-Market | Relapsed/Refractory Multiple Myeloma (RRMM) |
| Linvoseltamab NCT05730036 | Phase 3 | Relapsed Refractory Multiple Myeloma (RRMM) |
| Linvoseltamab NCT06910124 | Phase 2 | Multiple Myeloma |
| Linvoseltamab NCT05828511 | Phase 1/2 | Multiple Myeloma |
| Linvoseltamab NCT06292780 | Phase 1/2 | Relapsed/Refractory Systemic Light Chain Amyloidosis |
| linvoseltamab NCT06369467 | Phase 1 | Food Allergy |
Latest
No recent events.
Follow Linvoseltamab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.